• Free Investing e-Course
  • About
  • Advertise
  • Contact
  • Submit a Sponsored Post
Money Works Magazine
  • Life Sciences
  • Online Gaming
  • Real Estate
  • Download App
  • MORE
    • Technology
    • Personal Finance
    • Mining
DOWNLOAD YOUR COPY OF INVESTING IS FOR EVERYONE >
Money Works Magazine
  • Life Sciences
  • Online Gaming
  • Real Estate
  • Download App
  • MORE
    • Technology
    • Personal Finance
    • Mining
Money Works Magazine
Home Business

“Buzz on the Street” Show: AnPac Bio-Medical (NASDAQ: ANPC) Receives Immunology Testing Contract

Money Works Magazine by Money Works Magazine
September 16, 2020
in Business
0
“Buzz on the Street” Show: AnPac Bio-Medical (NASDAQ: ANPC) Receives Immunology Testing Contract
Share on FacebookShare on Twitter


FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “AnPac Bio Receives Major Immunology Testing Contract.”

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that the Company entered into a noteworthy sales contract in mid-August 2020 with Beijing Yuan Jian Health Management Co., Ltd. in China for the Company’s newly launched immunology test, AnPac Defense Medical Examination (ADME).  Beijing Yuan Jian Health Management has already been a client of AnPac for the past two years. The contract has a duration of 14 months and includes 20,000 paid ADME tests, with the expectation that the test is to be offered to end customers at multiple locations in China.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide and first in China among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of May 2020. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: Anpac Bio-Medical Science Co., Ltd.

For more corporate news on Anpac Bio-Medical Science Co., Ltd., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.


Written by financial buzz.
View the original article at here.
Financial Buzz
www.financialbuzz.com

Recommended

Pit wall collapses at Avesoro’s New Liberty mine in Liberia

Pit wall collapses at Avesoro’s New Liberty mine in Liberia

1 year ago
MSO Strength Drives American Cannabis Operator Index 16% Higher in August

MSO Strength Drives American Cannabis Operator Index 16% Higher in August

5 months ago
Facebook Twitter LinkedIn

MWM is your friendly source of knowledge on financial freedom via investment opportunities and financial planning to make your money work for you.

  • Submit a Sponsored Post
  • Contact
  • Privacy Policy

Get the latest financial tips and news.
Sign up today.

  • This field is for validation purposes and should be left unchanged.

© 2019 Money Works Magazine . All rights reserved.

  • Home
  • Life Sciences
  • Personal Finance
  • Online Gaming
  • Mining
  • Technology
  • How To Trade
  • Free e-Course
  • Money Works Magazine App

© 2019 Money Works Magazine . All rights reserved.